| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,953 |
8,963 |
$1.58M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
13,049 |
7,930 |
$1.42M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
563 |
389 |
$713K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,436 |
4,038 |
$649K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
5,359 |
1,369 |
$423K |
| G0378 |
Hospital observation service, per hour |
414 |
226 |
$308K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,035 |
570 |
$282K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,426 |
1,728 |
$210K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,582 |
2,180 |
$202K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,492 |
1,497 |
$178K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
2,069 |
1,429 |
$173K |
| 71046 |
Radiologic examination, chest; 2 views |
2,537 |
1,432 |
$155K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,406 |
784 |
$143K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
2,069 |
587 |
$134K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,959 |
1,212 |
$103K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,400 |
1,060 |
$95K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,302 |
1,539 |
$86K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,262 |
1,570 |
$84K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,738 |
1,726 |
$82K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
740 |
364 |
$79K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
420 |
236 |
$70K |
| 73562 |
|
660 |
394 |
$67K |
| 71045 |
Radiologic examination, chest; single view |
1,438 |
869 |
$62K |
| 80053 |
Comprehensive metabolic panel |
10,781 |
7,330 |
$50K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,249 |
1,840 |
$50K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
988 |
740 |
$48K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,636 |
923 |
$44K |
| 73610 |
|
309 |
216 |
$40K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
83 |
79 |
$40K |
| 73030 |
|
455 |
269 |
$39K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,393 |
7,544 |
$37K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,901 |
3,067 |
$36K |
| 73630 |
|
361 |
234 |
$33K |
| 64635 |
|
67 |
27 |
$30K |
| 80061 |
Lipid panel |
2,384 |
2,125 |
$25K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,069 |
957 |
$24K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,037 |
915 |
$22K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,035 |
913 |
$21K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
583 |
427 |
$21K |
| 87631 |
|
293 |
248 |
$20K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
164 |
120 |
$20K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
27 |
24 |
$19K |
| 97161 |
|
195 |
149 |
$17K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,797 |
1,268 |
$17K |
| 20553 |
|
495 |
203 |
$16K |
| 72100 |
|
106 |
85 |
$16K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
310 |
222 |
$14K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
165 |
151 |
$13K |
| 83735 |
|
5,017 |
3,260 |
$13K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,128 |
2,866 |
$12K |
| J3490 |
Unclassified drugs |
2,625 |
817 |
$12K |
| 85027 |
|
2,166 |
1,852 |
$11K |
| 64636 |
|
62 |
24 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
18,015 |
12,797 |
$10K |
| 64640 |
|
76 |
12 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,182 |
1,697 |
$8K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
1,781 |
961 |
$7K |
| 87081 |
|
1,517 |
1,322 |
$7K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
14 |
12 |
$7K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,027 |
870 |
$7K |
| 73130 |
|
50 |
29 |
$7K |
| 84484 |
|
2,302 |
1,187 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,180 |
914 |
$6K |
| 83655 |
|
548 |
508 |
$6K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
83 |
79 |
$6K |
| 80306 |
|
971 |
634 |
$5K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
217 |
147 |
$5K |
| 81001 |
|
3,398 |
2,363 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
113 |
67 |
$4K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
222 |
200 |
$4K |
| 71250 |
|
22 |
12 |
$4K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
77 |
24 |
$4K |
| 82607 |
|
532 |
441 |
$4K |
| 74018 |
|
30 |
25 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
199 |
181 |
$4K |
| 83690 |
|
1,175 |
807 |
$4K |
| 20611 |
|
43 |
14 |
$4K |
| 73110 |
|
23 |
18 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,712 |
1,146 |
$3K |
| 85610 |
|
2,224 |
1,322 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
380 |
193 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
805 |
570 |
$3K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
487 |
346 |
$3K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
53 |
26 |
$3K |
| 86140 |
|
1,000 |
704 |
$3K |
| 74019 |
|
31 |
24 |
$3K |
| 87077 |
|
509 |
388 |
$3K |
| 81003 |
|
2,095 |
1,683 |
$2K |
| 82570 |
|
587 |
515 |
$2K |
| 96376 |
|
47 |
26 |
$2K |
| 97162 |
|
28 |
24 |
$2K |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
15 |
12 |
$2K |
| 87186 |
|
406 |
301 |
$2K |
| 82043 |
|
425 |
380 |
$2K |
| 81025 |
|
406 |
317 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,691 |
1,048 |
$2K |
| 83880 |
|
176 |
106 |
$2K |
| 87430 |
|
193 |
131 |
$2K |
| 86738 |
|
165 |
140 |
$1K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
20 |
13 |
$1K |
| 87040 |
|
380 |
181 |
$1K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
64 |
61 |
$1K |
| 82728 |
|
148 |
102 |
$1K |
| 83605 |
|
342 |
203 |
$1K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
127 |
84 |
$1K |
| 76942 |
|
18 |
12 |
$1K |
| 84702 |
|
76 |
63 |
$934.46 |
| 84439 |
|
121 |
94 |
$904.11 |
| 85652 |
|
519 |
397 |
$886.51 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
248 |
141 |
$781.51 |
| 86850 |
|
119 |
91 |
$662.74 |
| 85651 |
|
348 |
266 |
$625.36 |
| 82746 |
|
68 |
53 |
$604.46 |
| 36416 |
|
160 |
150 |
$573.18 |
| 83540 |
|
119 |
91 |
$563.60 |
| 80050 |
General health panel |
66 |
65 |
$547.96 |
| 83550 |
|
80 |
66 |
$513.99 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
796 |
580 |
$418.64 |
| 87070 |
|
69 |
55 |
$384.90 |
| 82248 |
|
141 |
94 |
$333.48 |
| 0296T |
|
15 |
12 |
$263.50 |
| 82565 |
|
113 |
75 |
$246.64 |
| 82150 |
|
73 |
54 |
$237.13 |
| 84703 |
|
62 |
50 |
$235.83 |
| 99215 |
Prolong outpt/office vis |
14 |
12 |
$203.58 |
| 82947 |
|
63 |
61 |
$200.42 |
| 86592 |
|
80 |
75 |
$198.31 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
270 |
136 |
$194.67 |
| 99442 |
|
33 |
27 |
$168.00 |
| 86803 |
|
13 |
13 |
$164.18 |
| 82465 |
|
40 |
26 |
$160.20 |
| 85379 |
|
25 |
17 |
$145.79 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
35 |
30 |
$132.11 |
| 86901 |
|
102 |
75 |
$126.83 |
| 86900 |
|
102 |
75 |
$126.83 |
| 84145 |
|
16 |
13 |
$118.69 |
| 86038 |
|
18 |
12 |
$113.30 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
143 |
94 |
$105.68 |
| 87340 |
|
14 |
12 |
$100.21 |
| 87205 |
|
60 |
39 |
$98.65 |
| 85730 |
|
41 |
25 |
$98.29 |
| 82044 |
|
14 |
14 |
$52.80 |
| 85007 |
|
15 |
15 |
$24.48 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
22 |
12 |
$20.42 |
| 85018 |
|
15 |
13 |
$15.35 |
| S9982 |
Medical records copying fee, per page |
24 |
24 |
$12.00 |
| 83721 |
|
16 |
14 |
$8.79 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
19 |
12 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
21 |
13 |
$0.00 |